中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (8): 675-680.doi: 10.19401/j.cnki.1007-3639.2017.08.012

• 综述 • 上一篇    

Oncotype DX 21基因检测在ER阳性早期乳腺癌中的应用

章 颖 综述 柳光宇 审校   

  1. 复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海200032
  • 出版日期:2017-08-30 发布日期:2017-09-21
  • 通信作者: 柳光宇 E-mail: liugy123@yahoo.com

The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer

ZHANG Ying, LIU Guangyu   

  1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2017-08-30 Online:2017-09-21
  • Contact: LIU Guangyu E-mail: liugy123@yahoo.com

摘要: 在诸多评估雌激素受体(estrogen receptor,ER)阳性早期乳腺癌复发风险的多基因工具中,Oncotype DX 21基因检测因其独特的疗效预测作用而被广泛应用于淋巴结阴性患者。多项回顾性研究已证明其在淋巴结阳性人群同样具有预后预测价值,但前瞻性临床试验证据仍不充分。该检测能协同其他重要临床病理因素,影响乳腺癌患者的辅助治疗方案,且具较高的成本效益。该研究就21基因检测对早期乳腺癌患者的预后预测价值、独特优势、辅助治疗决策影响、成本效果和现存争议进行综述。

关键词: 乳腺癌, Oncotype DX, 21基因检测, 预后, 化疗

Abstract: Several multi-gene assays have been developed to predict the risk of recurrence in patients with early-stage, estrogen receptor (ER) positive breast cancer. Among them, Oncotype DX 21-gene assay is widely applied among node-negative patients because of its unique prediction of therapeutic benefit. Although many retrospective studies have proved its prognostic and predictive value in node-positive population, evidence from large prospective clinical trials remains insufficient. When combined with clinicopathological variables, the assay has been shown to impact adjuvant treatment decision making in a cost-effective manner. This article reviewed the available clinical evidence for the prognostic and predictive value, unique advantages, the effect on treatment decision making, cost-effectiveness and contradictories of 21-gene assay in early-stage luminal breast cancer patients.

Key words: Breast cancer, Oncotype DX, 21-gene assay, Prognosis, Chemotherapy